• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers use shock waves, nanoparticles to deliver chemo drugs

May 11, 2017 By Sarah Faulkner

ThyroidResearchers from the University of Turin demonstrated that combining shock waves with nanoparticles can help deliver chemotherapy to tumors in animal models. The team’s work was published in the journal, Endocrine-Related Cancer.

Researchers designed the treatment to use extracorporeal shock waves and nanobubbles to more effectively target the cancer drugs to the tumor site.

The team tested the approach on a mouse model of anaplastic thyroid cancer, which is very aggressive, rare and difficult to treat with conventional chemotherapy. A standard therapy for ATC does not exist and its only approved drug, doxorubicin, comes with painful side effects.

In this study, researchers found that doxorubicin-loaded nanobubbles combined with extracorporeal shock waves significantly reduced tumor volume compared to mice treated with just the nanobubbles, standard doxorubicin or nothing. The combo therapy also resulted in lower tumor weight, higher doxorubicin tumor content and more dying tumor cells, according to the team.

“This could be a feasible strategy for the treatment of this and other aggressive solid tumours in which standard chemotherapy remains the only option,” the study’s principal investigator said in prepared remarks. “Given the promising results of this preclinical study and the lack of a standard therapy for ATC, the next step will be conducting clinical trials with the hope of improving the cancer treatment and patient quality of life”.

Filed Under: Featured, Nanoparticles, Oncology, Pharmaceuticals, Research & Development Tagged With: University of Turin

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS